SCA
SRPT icon

SAC Capital Advisors’s Sarepta Therapeutics SRPT Stock Holding History

SAC Capital Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-641,600
Closed -$15.4M – 885
2014
Q1 		$15.4M Sell
641,600
-70,177
-10% -$1.79M 0.08% 324
2013
Q4 		$14.5M Sell
711,777
-248,523
-26% -$7.38M 0.08% 287
2013
Q3 		$45.4M Buy
960,300
+910,200
+1,817% +$35.1M 0.25% 110
2013
Q2 		$1.91M Buy
+50,100
New +$1.79M 0.01% 767

Other funds holding SRPT

Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

SAC Capital Advisors's SRPT Position: Q2 2014 in Review

SAC Capital Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2014, closing a stake of 641,600 shares — an estimated $15.4M sold.

SAC Capital Advisors first reported a position in SRPT in Q2 2013 and held it in 4 quarters. The position peaked at $45.4M in Q3 2013. 128 funds tracked by Wall St. Rank hold SRPT as of Q2 2014.

  • SAC Capital Advisors reported no remaining Sarepta Therapeutics position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 641,600 Sarepta Therapeutics shares in Q2 2014, an estimated $15.4M.
  • SAC Capital Advisors first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 4 quarters.
  • SAC Capital Advisors's Sarepta Therapeutics position peaked at $45.4M in Q3 2013.
  • 128 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.